Incidence of and Risk Factors for Adverse Drug Reactions in a Prospective Cohort of HIV-Infected Adults Initiating Protease Inhibitor--Containing Therapy, Clinical Infectious Diseases, vol.39, issue.2, pp.248-55, 2004. ,
DOI : 10.1086/422141
Predictors of protease inhibitor-associated adverse events, Biomedicine & Pharmacotherapy, vol.55, issue.6, pp.321-324, 2001. ,
DOI : 10.1016/S0753-3322(01)00070-1
Digoxin Level and Clinical Manifestations as Determinants in the Diagnosis of Digoxin Toxicity, Therapeutic Drug Monitoring, vol.22, issue.2, pp.163-171, 2000. ,
DOI : 10.1097/00007691-200004000-00004
Therapeutic Drug Monitoring of Tacrolimus in Clinical Transplantation, Therapeutic Drug Monitoring, vol.17, issue.6, pp.602-607, 1995. ,
DOI : 10.1097/00007691-199512000-00010
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma, Cancer, vol.13, issue.5, pp.1037-1084, 2000. ,
DOI : 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
Inc. Crixivan (indinavir sulfate) product monograph. West Point, 1997. ,
Antiviral Effect and Pharmacokinetic Interaction between Nevirapine and Indinavir in Persons Infected with Human Immunodeficiency Virus Type 1, The Journal of Infectious Diseases, vol.179, issue.5, pp.1116-1139, 1999. ,
DOI : 10.1086/314703
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study, AIDS, vol.14, issue.10, pp.1333-1342, 2000. ,
DOI : 10.1097/00002030-200007070-00005
Indinavir Concentrations and Antiviral Effect, Pharmacotherapy, vol.124, issue.6, pp.708-720, 1999. ,
DOI : 10.1097/00002030-199712000-00002
Treatment Failure of Nelfinavir-Containing Triple Therapy Can Largely Be Explained by Low Nelfinavir Plasma Concentrations, Therapeutic Drug Monitoring, vol.25, issue.1, pp.73-80, 2003. ,
DOI : 10.1097/00007691-200302000-00011
Indinavir Plasma Concentration and Adherence Score Are Codeterminant of Early Virologic Response in HIV-Infected Patients of the APROCO Cohort, Therapeutic Drug Monitoring, vol.27, issue.1, pp.63-70, 2005. ,
DOI : 10.1097/00007691-200502000-00013
Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching, Journal of Chromatography A, vol.692, issue.1-2, pp.45-52, 1995. ,
DOI : 10.1016/0021-9673(94)00608-C
Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography, Journal of Chromatography B: Biomedical Sciences and Applications, vol.744, issue.2, pp.227-267, 2000. ,
DOI : 10.1016/S0378-4347(00)00225-5
Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy, Fundamental and Clinical Pharmacology, vol.40, issue.3 ,
DOI : 10.1097/00002030-200305230-00007
Population pharmacokinetics and pharmacodynamics, in Pharmacokinetics: regulatory, industrial, academics perspectives. Library of congress, pp.411-449, 1995. ,
Statistical methods for population pharmacokinetic modelling Clinical safety data management : definitions and standards for expedited reporting, Stat Methods Med Res fed regist, vol.760, issue.17, pp.63-8411284, 1995. ,
DOI : 10.1191/096228098670696372
Changes in renal function associated with indinavir, AIDS, vol.12, issue.18, pp.249-54, 1998. ,
DOI : 10.1097/00002030-199818000-00003
Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients, AIDS, vol.12, issue.18, pp.2433-2440, 1998. ,
DOI : 10.1097/00002030-199818000-00012
Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients, Aids, vol.13, issue.4, pp.473-481, 1999. ,
DOI : 10.1097/00002030-199903110-00005
HIV-protease inhibitors, N Engl J Med, vol.338, pp.1281-92, 1998. ,
Crystalluria and Urinary Tract Abnormalities Associated with Indinavir, Annals of Internal Medicine, vol.127, issue.2, pp.119-144, 1997. ,
DOI : 10.7326/0003-4819-127-2-199707150-00004
Indinavir, Drugs, vol.58, issue.6, pp.1165-203, 1999. ,
DOI : 10.2165/00003495-199958060-00011
Pharmacokinetic Variability Caused by Gender: Do Women Have Higher Indinavir Exposure Than Men?, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.29, issue.1, pp.101-103, 2002. ,
DOI : 10.1097/00042560-200201010-00014
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.23, issue.3, pp.236-281, 2000. ,
DOI : 10.1097/00126334-200003010-00004
Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions 17 ,
Estimation of human body surface area from height and weight, Cancer Chemother Rep, vol.54, pp.225-260, 1970. ,
Adverse effects of antiretroviral therapy, The Lancet, vol.356, issue.9239, pp.1423-1453, 2000. ,
DOI : 10.1016/S0140-6736(00)02854-3
Prediction of Creatinine Clearance from Serum Creatinine, Nephron, vol.16, issue.1, pp.31-41, 1976. ,
DOI : 10.1159/000180580
Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients, HIV Medicine, vol.14, issue.4, pp.307-320, 2004. ,
DOI : 10.1097/00002030-199910010-00001
Methods for categorizing a prognostic variable in a multivariable setting, Statistics in Medicine, vol.4, issue.4, pp.559-71, 2003. ,
DOI : 10.1002/sim.1333
Influence of Environmental Temperature on Incidence of Indinavir???Related Nephrolithiasis, Clinical Infectious Diseases, vol.29, issue.2, pp.422-427, 1999. ,
DOI : 10.1086/520226
High Indinavir Cmin Is Associated With Higher Toxicity in Patients on Indinavir-Ritonavir 800/100 mg Twice-Daily Regimen, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.29, issue.4, pp.374-381, 2002. ,
DOI : 10.1097/00126334-200204010-00008
The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring, AIDS, vol.13, issue.15, pp.2083-2092, 1999. ,
DOI : 10.1097/00002030-199910220-00011
Therapeutic drug monitoring as a tool in treating HIV infection, AIDS, vol.15, issue.5, pp.171-181, 2001. ,
DOI : 10.1097/00002030-200100005-00021
A Critical Evaluation of the Therapeutic Range of Indinavir, Annals of Pharmacotherapy, vol.1, issue.7-8, pp.1230-1237, 2002. ,
DOI : 10.1345/aph.1A016
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients, AIDS, vol.15, issue.1, pp.71-76, 2001. ,
DOI : 10.1097/00002030-200101050-00011
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals, AIDS, vol.17, issue.8, pp.1157-65, 2003. ,
DOI : 10.1097/00002030-200305230-00007